NCNA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	31 352.00
Średni wolumen	76 368.00
Kapitalizacja rynkowa	8.13M
EPS	£0 ( 2024-04-01 )
Następna data zysków	( £-3.31 ) 2024-05-15
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.230
ATR14	£0.0290 (0.75%)

NuCana PLC Korelacja

10 Najbardziej pozytywne korelacje
ARVL	0.89
ATRC	0.887
SQL	0.884
ARIZ	0.868
MBIO	0.867
PDSB	0.864
EZGO	0.86
FIVE	0.857
AMRS	0.853
VWE	0.851

10 Najbardziej negatywne korelacje
MOTNU	-0.892
NN	-0.889
LWAY	-0.886
CENX	-0.885
QRHC	-0.869
CURI	-0.868
GRIN	-0.862
PPTA	-0.86
SMTC	-0.86
DBDR	-0.856

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NuCana PLC Finanse

Annual	2023
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.520

FY	2023
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.520

FY	2022
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.620

FY	2021
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.780

Financial Reports:

No articles found.

NuCana PLC

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.